OTC, Rx Drug Risk Equation May Be Altered In Upcoming GMP Plan
This article was originally published in The Tan Sheet
Executive Summary
FDA is considering applying different levels of scrutiny to OTC and Rx drugs as part of its new risk-based approach to pharmaceutical Good Manufacturing Practices
You may also be interested in...
FDA Manufacturing Inspections To Focus On Sterile, New Facilities In FY 2003
FDA will continue to emphasize inspection of sterile manufacturing facilities in fiscal year 2003, Division of Manufacturing & Product Quality Director Joseph Famulare said Dec. 11
FDA Manufacturing Inspections To Focus On Sterile, New Facilities In FY 2003
FDA will continue to emphasize inspection of sterile manufacturing facilities in fiscal year 2003, Division of Manufacturing & Product Quality Director Joseph Famulare said Dec. 11
FDA Manufacturing Inspections To Focus On Sterile, New Facilities In FY 2003
FDA will continue to emphasize inspection of sterile manufacturing facilities in fiscal year 2003, Division of Manufacturing & Product Quality Director Joseph Famulare said Dec. 11